← Leaderboards
Lori Rink
Research Inst Of Fox Chase Can Ctr
$4,773,698
Attributed
$5,408,022
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $979.6K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,408,022 · 5
By mechanism
R01$4,466,568 · 3
R00$739,532 · 1
K99$201,922 · 1
Top collaborators
- Margaret Von Mehren3 shared
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsCellsMalignant NeoplasmsGastrointestinal Stromal TumorsResistanceIn VivoXenograft ModelTumorPdgfra GeneGenesTumor Cell LineOncogenicPreventRefractoryResponseImatinib MesylateCombined Modality TherapyNeoplastic CellPre-ClinicalRouteSignal TransductionMemberInhibitor/AntagonistRecurrence
Grant awards (15)
Designing selective kinase inhibitors via deep learning$549,557
R01 · FY2025 · GM · contact PI
Elucidating the critical role of Wee1 in GIST$430,050
R01 · FY2025 · CA · contact PI
Designing selective kinase inhibitors via deep learning$549,557
R01 · FY2024 · GM · contact PI
Elucidating the critical role of Wee1 in GIST$408,548
R01 · FY2024 · CA · contact PI
Elucidating the critical role of Wee1 in GIST$430,050
R01 · FY2023 · CA · contact PI
Exploiting vulnerabilities in GIST using novel combination therapies$427,763
R01 · FY2021 · CA · contact PI
Exploiting vulnerabilities in GIST using novel combination therapies$427,763
R01 · FY2020 · CA · contact PI
Exploiting vulnerabilities in GIST using novel combination therapies$406,054
R01 · FY2019 · CA · contact PI
Exploiting vulnerabilities in GIST using novel combination therapies$418,613
R01 · FY2018 · CA · contact PI
Exploiting vulnerabilities in GIST using novel combination therapies$418,613
R01 · FY2017 · CA · contact PI
ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor$249,000
R00 · FY2016 · CA · contact PI
ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor$249,000
R00 · FY2015 · CA · contact PI
ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor$241,532
R00 · FY2014 · CA · contact PI
ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor$100,961
K99 · FY2013 · CA · contact PI
ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor$100,961
K99 · FY2012 · CA · contact PI